Tag: prothrombin complex concentrate market size

Uncover key drivers, emerging technologies, and competitive movements shaping the prothrombin complex concentrate market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Prothrombin Complex Concentrate Market between 2026 and 2030?

The market for prothrombin complex concentrate has demonstrated substantial growth in recent years. Its value is projected to rise from $1.38 billion in 2025 to $1.48 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. This historical expansion can be attributed to factors such as the increasing prevalence of coagulation disorders, the expansion of emergency care infrastructure, the availability of plasma-derived therapies, a rise in surgical procedure volumes, and the growing use of anticoagulant medications.

The prothrombin complex concentrate market is projected for substantial expansion in the coming years. This market is forecast to reach $1.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. This expansion during the projection period stems from several factors, including a heightened need for swift coagulation treatments, escalating investments in developing recombinant factors, an increase in trauma care infrastructure, an intensified emphasis on ensuring patient safety in anticoagulant treatments, and the wider acceptance of standardized bleeding management guidelines. Key developments anticipated over the forecast timeframe involve the growing acceptance of four-factor PCC products, an increased application of PCC for quick reversal of anticoagulation, a heightened requirement for immediate bleeding management solutions, the broadened availability of recombinant coagulation products, and a stronger emphasis on fast-acting hemostatic treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which Drivers Are Expected To Impact The Prothrombin Complex Concentrate Market During The Forecast Period?

The expansion of the prothrombin complex concentrate market is anticipated to be spurred by the rising occurrence of bleeding disorders. These conditions, characterized by inadequate blood clotting and subsequent excessive bleeding due to deficient or faulty clotting factors or platelets, are becoming more common. This increase is primarily attributed to a greater incidence of genetic disorders such as hemophilia, a surge in liver disease cases, the expanding application of anticoagulant medications, and a higher frequency of vitamin K deficiencies. Prothrombin complex concentrate offers a solution by quickly restoring clotting factors, which are crucial for effective blood coagulation and stopping bleeding. For example, a report from the World Federation of Hemophilia, published in October 2024, revealed that in 2023, there were 179,703 documented cases of hemophilia A. Of these, 162,040 cases, accounting for 90%, were male, 6,990 cases were female, and 10,673 cases, or 6%, did not specify the patient’s sex. Consequently, the growing prevalence of bleeding disorders is a key factor propelling the growth of the prothrombin complex concentrate market.

Which Segments Are Driving Activity In The Prothrombin Complex Concentrate Market?

The prothrombin complex concentrate market covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous, Intravenous Infusion Variants, Intravenous Bolus Administration

4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users

Subsegments:

1) By 3-Factor PCC Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By 4-Factor PCC Typ: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Other Products: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products

How Are New Market Trends Shaping The Landscape Of The Prothrombin Complex Concentrate Market?

Key companies in the prothrombin complex concentrate market are actively developing novel formulations, like lyophilized powder, to improve stability, optimize storage, and simplify administration. This lyophilized powder is a freeze-dried preparation that removes water, thereby extending its shelf life and preserving its potency. This allows for improved storage conditions and rapid reconstitution for emergency use. For instance, in July 2023, Octapharma USA Inc., a US-based biotechnology company, obtained FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for urgent warfarin reversal during surgeries and invasive procedures. This approval was granted based on the LEX-209 trial, which revealed 94.6% hemostatic efficacy, demonstrating its effectiveness comparable to Kcentra. This progression emphasizes the industry’s dedication to advancing coagulation therapies to enhance patient outcomes in critical care situations.

Which Major Firms Are Strengthening Their Position In The Prothrombin Complex Concentrate Market?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd BPL, Prothya Biosolutions B.V., China Biologic Products Holdings Inc., Intas Pharmaceuticals Ltd, Biotest AG, Octapharma Plasma, Kamada Ltd, SK Plasma Co. Ltd, Reliance Life Sciences, Bharat Serums And Vaccines Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Prothrombin Complex Concentrate Market?

North America was the largest region in the prothrombin complex concentrate market in 2025. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prothrombin Complex Concentrate Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

Browse Through More Reports Similar to the Global Prothrombin Complex Concentrate Market 2026, By The Business Research Company

Juice Concentrates Market Report 2026

https://www.thebusinessresearchcompany.com/report/juice-concentrates-global-market-report

Bilirubin Blood Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/bilirubin-blood-test-global-market-report

Proteomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/proteomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Prothrombin Complex Concentrate Market In The Coming Years?

In recent times, the prothrombin complex concentrate market has seen robust growth. It’s projected that the market size will rise from $1.29 billion in 2024 to $1.38 billion in 2025, recording a compound annual growth rate (CAGR) of 6.7%. The historical growth can be credited to an increase in bleeding disorders, more frequent use in counteracting warfarin, heightened awareness around coagulation treatments, an increase in surgical procedures, and a rise in trauma cases.

It is anticipated that the prothrombin complex concentrate market will undergo substantial growth in the forthcoming years, potentially rising to an estimated $1.83 billion by 2029 at a compound annual growth rate (CAGR) of 7.3%. This expected growth in the prediction period is primarily due to the escalating demand for swift coagulation treatments, a heightened frequency of hemophilia and liver diseases, an increase in emergency medicine application rates, the broadening use in cardiac surgeries, and increased health care spending. The forecast period is also expected to observe significant trends such as the use of AI in diagnostics, advances in recombinant coagulation factors, the arrival of next-generation recombinant PCCs, personalized dosing algorithms’ implementation, and progresses in blood plasma product technologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

What Drivers Are Accelerating Expansion Of The Prothrombin Complex Concentrate Market?

The escalating frequency of bleeding disorders is set to drive the expansion of the prothrombin complex concentrate market. Medical conditions that prevent the blood from clotting effectively, resulting in excessive bleeding due to missing or non-functioning clotting factors or platelets, are known as bleeding disorders. These complications are on the rise, mainly due to the growing occurrence of genetic disorders like hemophilia, increased instances of liver disease, widened usage of anticoagulant medicines, and a surge in the number of vitamin K deficiencies. Prothrombin complex concentrate provides an effective treatment for bleeding disorders as it replenishes clotting factors swiftly, which are vital for effective blood coagulation and hemostasis. In a specific case reported by the National Library of Medicine, a medical library based in the U.S., in November 2023, a study was conducted on 10,276 individuals with hemophilia in 87 treatment centers spread over 40 countries in the year 2022. Approximately 49% of these participants had serious hemophilia, 99% were male, and 85% were diagnosed with Hemophilia A. Of this group, 67% of the patients hailed from low to middle-income countries. Thus, the rising frequency of bleeding disorders is catalyzing the expansion of the prothrombin complex concentrate market.

How Is The Global Prothrombin Complex Concentrate Market Broken Down By Segment?

The prothrombin complex concentratemarket covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates; 4-Factor Prothrombin Complex Concentrates; Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B); Trauma; Life-Threatening Coagulopathy With Acute Bleeding; Warfarin-Associated Acute, Life-Threatening Bleeding; Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous; Subcutaneous; Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers; Specialty Clinics; Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC); High-Dose 3-Factor Prothrombin Complex Concentrates (PCC); Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC); High-Dose 4-Factor Prothrombin Complex Concentrates (PCC); Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes; Plasma-Derived Coagulation Factor Complexes; Combination Therapy Products

Which Notable Trends Are Transforming The Prothrombin Complex Concentrate Market Outlook?

Key players in the prothrombin complex concentrate market are concentrating their efforts on the creation of novel formulations like lyophilized powder. This reformulation looks at improving stability, streamlining administration, and enhancing storage capabilities. Lyophilized powder, a freeze-dried formulation, extends shelf life and potency by removing water. It gives the advantage of improved storage conditions and quick reconstitution during emergencies. As an illustrative example, in July 2023, the US-based biotech enterprise, Octapharma USA Inc., secured FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) designed for immediate warfarin reversal during surgeries and invasive procedures. The approval was anchored on the LEX-209 trial, which demonstrated 94.6% hemostatic efficacy, thereby equating it with Kcentra. Such advancements reiterate the industry’s commitment to optimize coagulation treatments in order to improve patient results in critical care environments.

Which Firms Are Making The Biggest Impact In The Prothrombin Complex Concentrate Market?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., China Biologic Products Holdings Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Prothrombin Complex Concentrate Market?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

Browse Through More Reports Similar to the Global Prothrombin Complex Concentrate Market 2025, By The Business Research Company

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Prothrombin Complex Concentrate Market Covering 2025–2034?

The prothrombin complex concentrate market size has exhibited substantial growth in recent years. This market is projected to expand from $1.29 billion in 2024 to $1.38 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.7%. The historical expansion can be attributed to several factors, including an increase in the prevalence of bleeding disorders, heightened use in warfarin reversal, a growing awareness of coagulation therapies, the expansion of surgical procedures, and an uptick in trauma cases.

The prothrombin complex concentrate market is anticipated to experience substantial expansion in the coming years. It is projected to reach $1.83 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.3%. This growth during the forecast period is primarily driven by the increasing demand for rapid coagulation therapies, the rising prevalence of hemophilia and liver diseases, greater adoption in emergency medicine, expanding applications in cardiac surgeries, and growing healthcare expenditure. Furthermore, significant trends expected in this period include the integration of AI-driven diagnostics, advancements in recombinant coagulation factors, the emergence of next-generation recombinant pccs, customized dosing algorithms, and further advancements in blood plasma products.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which Drivers Are Impacting The Prothrombin Complex Concentrate Market?

The growing occurrence of bleeding disorders is anticipated to drive the expansion of the prothrombin complex concentrate market. These medical conditions involve blood that does not clot effectively, resulting in excessive bleeding due to absent or malfunctioning clotting factors or platelets. The increase in bleeding disorders is largely due to the rising prevalence of genetic conditions such as hemophilia, a surge in liver disease cases, the growing use of anticoagulant medications, and a higher incidence of vitamin K deficiencies. Prothrombin complex concentrate effectively treats these disorders by rapidly replenishing crucial clotting factors necessary for proper blood coagulation and hemostasis. For example, in November 2023, the National Library of Medicine, a U.S.-based medical library, stated that a 2022 study involving 10,276 individuals with hemophilia was carried out across 87 treatment centers in 40 countries. The findings indicated that nearly 49% of the participants had severe hemophilia, 99% were male, and 85% were diagnosed with hemophilia A. Additionally, 67% of the patients were from low- and middle-income countries. This demonstrates that the increasing prevalence of bleeding disorders is indeed fostering the growth of the prothrombin complex concentrate market.

What Are The Major Segment Categories Driving The Prothrombin Complex Concentrate Market Growth?

The prothrombin complex concentratemarket covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates; 4-Factor Prothrombin Complex Concentrates; Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B); Trauma; Life-Threatening Coagulopathy With Acute Bleeding; Warfarin-Associated Acute, Life-Threatening Bleeding; Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous; Subcutaneous; Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers; Specialty Clinics; Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC); High-Dose 3-Factor Prothrombin Complex Concentrates (PCC); Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC); High-Dose 4-Factor Prothrombin Complex Concentrates (PCC); Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes; Plasma-Derived Coagulation Factor Complexes; Combination Therapy Products

Which Market Trends Are Creating New Opportunities In The Prothrombin Complex Concentrate Industry?

Leading companies in the prothrombin complex concentrate market are developing innovative formulations, such as lyophilized powder, to enhance stability, improve storage, and simplify administration. This lyophilized powder is a freeze-dried formulation designed to remove water, thereby increasing shelf life and maintaining potency. This advancement facilitates better storage conditions and rapid reconstitution for emergency use. For instance, in July 2023, Octapharma USA Inc., a US-based biotechnology company, received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) intended for urgent warfarin reversal in surgeries and invasive procedures. This approval was based on the LEX-209 trial, which demonstrated 94.6% hemostatic efficacy, proving it as effective as Kcentra. This progress underscores the industry’s focus on improving coagulation therapies to enhance patient outcomes in critical care settings.

Which Leading Players Are Enhancing Their Prothrombin Complex Concentrate Market Presence Worldwide?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., China Biologic Products Holdings Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

How Is Prothrombin Complex Concentrate Market Demand Varying Across Different Regions?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Prothrombin Complex Concentrate Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

Browse Through More Reports Similar to the Global Prothrombin Complex Concentrate Market 2025, By The Business Research Company

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Prothrombin Complex Concentrate Market From 2025 To 2029?

The market size of prothrombin complex concentrate has seen substantial progress in the past few years. The market value is set to increase from $1.29 billion in 2024 to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.7%. The remarkable growth during the historical period is primarily attributed to the upsurge in bleeding disorders’ prevalence, the expansion in the use of warfarin reversal, the increasing cognizance regarding coagulation treatments, the broadening scope of surgical procedures and the inflating cases of trauma.

The market for prothrombin complex concentrate is projected to experience robust expansion in the coming years. It is forecasted to reach $1.83 billion in 2029, with a compound annual growth rate of 7.3%. This predicted rise during the forecast period is associated with an increased demand for quick coagulation treatments, a surge in hemophilia and liver disease incidence, a growing use in emergency medicine, broader usage in heart surgeries, and escalating healthcare spending. Key market trends over the forecast period encompass the incorporation of AI-powered diagnostics, progress in recombinant coagulation factors, the advent of next-generation recombinant pccs, personalized dosing algorithms, and improvements in blood plasma products.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which Primay Drivers Are Accelerating Growth in the Prothrombin Complex Concentrate Market?

An uptick in the occurrence of bleeding disorders is predicted to stimulate the advancement of the prothrombin complex concentrate market. Bleeding disorders, which cause abnormal blood clotting that can lead to excessive bleeding due to faulty or missing clotting factors or platelets, are experiencing growth primarily due to the escalating incidence of genetic conditions like hemophilia, a rise in liver disease cases, increased use of anticoagulant medications, and an elevated rate of vitamin K deficiencies. Prothrombin complex concentrate combats bleeding disorders by quickly replenishing clotting factors, critical elements for successful blood coagulation and hemostasis. For example, in November 2023, the U.S.-based National Library of Medicine reported on a study from 2022 involving 10,276 persons with hemophilia, carried out in 87 treatment centers across 40 countries. Approximately 49% of these participants had severe hemophilia, 99% were male, and 85% were diagnosed with hemophilia A. Also, 67% of the patients hailed from low and medium-income countries. Therefore, the surging incidence of bleeding disorders is fuelling the expansion of the prothrombin complex concentrate market.

Which Primary Segments of the Prothrombin Complex Concentrate Market Are Driving Growth and Industry Transformations?

The prothrombin complex concentratemarket covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates; 4-Factor Prothrombin Complex Concentrates; Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B); Trauma; Life-Threatening Coagulopathy With Acute Bleeding; Warfarin-Associated Acute, Life-Threatening Bleeding; Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous; Subcutaneous; Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers; Specialty Clinics; Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC); High-Dose 3-Factor Prothrombin Complex Concentrates (PCC); Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC); High-Dose 4-Factor Prothrombin Complex Concentrates (PCC); Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes; Plasma-Derived Coagulation Factor Complexes; Combination Therapy Products

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Prothrombin Complex Concentrate Market?# Market?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Prothrombin Complex Concentrate Industry Dynamics?

Leading companies in the prothrombin complex concentrate market are focusing on innovation in formulations like the lyophilized powder to boost stability, streamline administration procedures, and enhance the storage ability. Lyophilized powder, which is a formulation that eliminates water by freeze-drying, results in a longer shelf life and sustains potency, enabling more efficient storage and swift reconstitution during emergencies. For instance, Octapharma USA Inc., an American biotech firm, received clearance from the FDA for Balfaxar, a 4F-PCC for immediate Warfarin reversal during surgeries and invasive procedures, in July 2023. The approval came on the back of the LEX-209 trial, which demonstrated a 94.6% hemostatic efficacy, establishing it as equitably effective as Kcentra. This progress highlights the sector’s commitment to enhance coagulation treatments for better patient results in intense care situations.

View the full report here:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

What Parameters Are Used to Define the Prothrombin Complex Concentrate Market?

Prothrombin complex concentrate (PCC) is a medication containing clotting factors used to treat or prevent bleeding in patients with coagulation disorders. It is administered intravenously to rapidly restore clotting factor levels in conditions such as hemophilia, warfarin reversal, and severe bleeding episodes.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23488

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Prothrombin Complex Concentrate Market Size Changed, over the years?

In recent times, the prothrombin complex concentrate market has demonstrated significant growth. It is projected to expand from $1.29 billion in 2024 to $1.39 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The growth experienced during the historical period is mainly due to an increased prevalence of bleeding disorders, a rise in the use of warfarin reversal, an enhanced awareness about coagulation therapies, an upsurge in surgical procedures, and a rise in trauma cases.

How Much Will the Prothrombin Complex Concentrate Market Be Worth in 2029?

Anticipations are high for the prothrombin complex concentrate market as it is poised to experience substantial expansion in the upcoming years. The market size is projected to escalate to $1.86 billion in 2029, expanding at a compound annual growth rate (CAGR) of 7.6%. This surge over the forecast period can be associated with the increasing need for quick coagulation treatments, heightened occurrence of hemophilia and liver disorders, growing use in emergency medical care, widening use cases in heart surgeries, and a rise in healthcare spending. The forecast period also unveils major trends such as the use of AI-powered diagnostic tools, progress in recombinant coagulation factors, development of next-gen recombinant pccs, the creation of tailored dosing algorithms, and advancements in blood plasma product technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which is the Largest Company in the Prothrombin Complex Concentrate Market?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., China Biologic Products Holdings Inc.

What Are the Main Market Drivers in the Prothrombin Complex Concentrate Industry?

The prothrombin complex concentrate market’s growth is expected to be stimulated by an upsurge in bleeding disorders. These are conditions where the blood’s ability to clot is impaired, resulting in excessive bleeding due to faulty or absent clotting factors or platelets. The increase in bleeding disorders is predominantly due to the rising occurrence of genetic diseases like hemophilia, ascending liver disease cases, escalating use of anticoagulant drugs, and an elevated incidence of vitamin K shortages. Prothrombin complex concentrate aids in the treatment of these disorders by swiftly restoring clotting factors critical for effective blood coagulation and hemostasis. As an example, a study comprising 10,276 individuals with hemophilia was undertaken across 87 treatment centers in 40 countries according to the U.S.-based National Library of Medicine in November 2023. About half of these participants had severe hemophilia, with 99% being male and 85% diagnosed with hemophilia A. Furthermore, 67% of these patients hailed from low- to middle-income countries. Thus, the escalating prevalence of bleeding disorders is boosting the prothrombin complex concentrate market’s growth. A surge in anticoagulant prescriptions caused by a rising incidence of cardiovascular diseases is anticipated to drive future growth in the prothrombin complex concentrate market. An anticoagulant is a compound that discourages or dilutes clot formation by inhibiting platelet aggregation or coagulation factors. The elevated prescription rate for anticoagulants can be attributed to an increase in cardiovascular diseases, an aging populace, widening clinical signs, enhanced screening protocols, and progress in anticoagulant therapy. Prothrombin complex concentrate counteracts anticoagulants’ effects by quickly replacing clotting factors and reinstating hemostasis in patients with excessive bleeding or immediate surgical needs. For instance, the UK-based National Health Service reported in November 2023 that an additional 460,000 individuals began anticoagulant medication in 2022, leading to over 24 million prescriptions given to patients. This helped prevent an estimated 17,000 strokes and 4,000 deaths. Therefore, the expanding anticoagulant prescription rate is propelling the prothrombin complex concentrate market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

How Is the Prothrombin Complex Concentrate Market Segments Structured?

The prothrombin complex concentrate market covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products

What Strategic Trends Are Transforming the Prothrombin Complex Concentrate Market?

Noteworthy companies in the prothrombin complex concentrate market are creating novel formulations like lyophilized powder to augment stability, facilitate storage, and make administration easier. Lyophilized powder is a freeze-dried mixture that dehydrates to prolong shelf life and preserve potency. This facilitates improved storage conditions and fast reconstitution for urgent application. For example, in July 2023, Octapharma USA Inc., a biotech company from the US, secured FDA authorization for Balfaxar, a 4-factor prothrombin complex concentrate (4F-PCC) used for immediate warfarin reversal in surgical and invasive processes. The approval arose from the LEX-209 trial, which demonstrated a 94.6% hemostatic efficacy, establishing its effectiveness equivalent to Kcentra. This technological leap highlights the sector’s commitment to the enhancement of coagulation treatments to improve patient results in crucial care situations.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

Which Global Regions Offer the Highest Growth in the Prothrombin Complex Concentrate Market?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23488

This Report Delivers Insight On:

1. How big is the prothrombin complex concentrate market, and how is it changing globally?

2. Who are the major companies in the prothrombin complex concentrate market, and how are they performing?

3. What are the key opportunities and risks in the prothrombin complex concentrate market right now?

4. Which products or customer segments are growing the most in the prothrombin complex concentrate market?

5. What factors are helping or slowing down the growth of the prothrombin complex concentrate market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Prothrombin Complex Concentrate Market Size Changed, over the years?

In recent times, the prothrombin complex concentrate market has demonstrated significant growth. It is projected to expand from $1.29 billion in 2024 to $1.39 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The growth experienced during the historical period is mainly due to an increased prevalence of bleeding disorders, a rise in the use of warfarin reversal, an enhanced awareness about coagulation therapies, an upsurge in surgical procedures, and a rise in trauma cases.

How Much Will the Prothrombin Complex Concentrate Market Be Worth in 2029?

Anticipations are high for the prothrombin complex concentrate market as it is poised to experience substantial expansion in the upcoming years. The market size is projected to escalate to $1.86 billion in 2029, expanding at a compound annual growth rate (CAGR) of 7.6%. This surge over the forecast period can be associated with the increasing need for quick coagulation treatments, heightened occurrence of hemophilia and liver disorders, growing use in emergency medical care, widening use cases in heart surgeries, and a rise in healthcare spending. The forecast period also unveils major trends such as the use of AI-powered diagnostic tools, progress in recombinant coagulation factors, development of next-gen recombinant pccs, the creation of tailored dosing algorithms, and advancements in blood plasma product technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which is the Largest Company in the Prothrombin Complex Concentrate Market?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., China Biologic Products Holdings Inc.

What Are the Main Market Drivers in the Prothrombin Complex Concentrate Industry?

The prothrombin complex concentrate market’s growth is expected to be stimulated by an upsurge in bleeding disorders. These are conditions where the blood’s ability to clot is impaired, resulting in excessive bleeding due to faulty or absent clotting factors or platelets. The increase in bleeding disorders is predominantly due to the rising occurrence of genetic diseases like hemophilia, ascending liver disease cases, escalating use of anticoagulant drugs, and an elevated incidence of vitamin K shortages. Prothrombin complex concentrate aids in the treatment of these disorders by swiftly restoring clotting factors critical for effective blood coagulation and hemostasis. As an example, a study comprising 10,276 individuals with hemophilia was undertaken across 87 treatment centers in 40 countries according to the U.S.-based National Library of Medicine in November 2023. About half of these participants had severe hemophilia, with 99% being male and 85% diagnosed with hemophilia A. Furthermore, 67% of these patients hailed from low- to middle-income countries. Thus, the escalating prevalence of bleeding disorders is boosting the prothrombin complex concentrate market’s growth. A surge in anticoagulant prescriptions caused by a rising incidence of cardiovascular diseases is anticipated to drive future growth in the prothrombin complex concentrate market. An anticoagulant is a compound that discourages or dilutes clot formation by inhibiting platelet aggregation or coagulation factors. The elevated prescription rate for anticoagulants can be attributed to an increase in cardiovascular diseases, an aging populace, widening clinical signs, enhanced screening protocols, and progress in anticoagulant therapy. Prothrombin complex concentrate counteracts anticoagulants’ effects by quickly replacing clotting factors and reinstating hemostasis in patients with excessive bleeding or immediate surgical needs. For instance, the UK-based National Health Service reported in November 2023 that an additional 460,000 individuals began anticoagulant medication in 2022, leading to over 24 million prescriptions given to patients. This helped prevent an estimated 17,000 strokes and 4,000 deaths. Therefore, the expanding anticoagulant prescription rate is propelling the prothrombin complex concentrate market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

How Is the Prothrombin Complex Concentrate Market Segments Structured?

The prothrombin complex concentrate market covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products

What Strategic Trends Are Transforming the Prothrombin Complex Concentrate Market?

Noteworthy companies in the prothrombin complex concentrate market are creating novel formulations like lyophilized powder to augment stability, facilitate storage, and make administration easier. Lyophilized powder is a freeze-dried mixture that dehydrates to prolong shelf life and preserve potency. This facilitates improved storage conditions and fast reconstitution for urgent application. For example, in July 2023, Octapharma USA Inc., a biotech company from the US, secured FDA authorization for Balfaxar, a 4-factor prothrombin complex concentrate (4F-PCC) used for immediate warfarin reversal in surgical and invasive processes. The approval arose from the LEX-209 trial, which demonstrated a 94.6% hemostatic efficacy, establishing its effectiveness equivalent to Kcentra. This technological leap highlights the sector’s commitment to the enhancement of coagulation treatments to improve patient results in crucial care situations.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

Which Global Regions Offer the Highest Growth in the Prothrombin Complex Concentrate Market?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23488

This Report Delivers Insight On:

1. How big is the prothrombin complex concentrate market, and how is it changing globally?

2. Who are the major companies in the prothrombin complex concentrate market, and how are they performing?

3. What are the key opportunities and risks in the prothrombin complex concentrate market right now?

4. Which products or customer segments are growing the most in the prothrombin complex concentrate market?

5. What factors are helping or slowing down the growth of the prothrombin complex concentrate market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model